Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.  

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Amid tough competition, Novartis makes case for rheumatology...

Swiss pharma hopes to bounce back from Q1 sales disappointment

Novartis trumpets long-term data for Cosentyx in psoriasis

Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals.